Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tinnitus 1Ototoxicity 1Lung Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Deafness 1

Interventions

pembrolizumab 29Paclitaxel 7Magnetic Resonance Spectroscopy 7Cisplatin 7Pemetrexed 6Docetaxel 6Carboplatin 6Standard of Care 5Radiotherapy 5Nivolumab 5Drug Therapy 5Specimen Handling 4Gemcitabine 4Cetuximab 4Blood Specimen Collection 4epacadostat 3X-Rays 3Surveys and Questionnaires 3Practice Guidelines as Topic 3Oncolytic Virotherapy 3Nicotine 3Fluorouracil 3Filgrastim 3Cyclophosphamide 3Bupropion 3Bortezomib 3Biopsy 3spartalizumab 2selpercatinib 2sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × ebselen × Head & Neck × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡